S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?

Rezolute (RZLT) Stock Price, News & Analysis

$2.55
+0.31 (+13.84%)
(As of 03/28/2024 ET)
Today's Range
$2.21
$2.69
50-Day Range
$0.97
$2.24
52-Week Range
$0.72
$2.69
Volume
594,499 shs
Average Volume
310,013 shs
Market Capitalization
$101.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.67

Rezolute MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
239.9% Upside
$8.67 Price Target
Short Interest
Healthy
0.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.58mentions of Rezolute in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$305,326 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.06) to ($1.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.16 out of 5 stars

Medical Sector

199th out of 938 stocks

Pharmaceutical Preparations Industry

83rd out of 417 stocks

RZLT stock logo

About Rezolute Stock (NASDAQ:RZLT)

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

RZLT Stock Price History

RZLT Stock News Headlines

3 Stocks Insiders Are Buying That Analysts Love (RZLT)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Rezolute appoints Daron Evans as CFO
Rezolute GAAP EPS of -$0.28 in-line
Rezolute Reports First Quarter Fiscal 2024 Results
See More Headlines
Receive RZLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RZLT
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.67
High Stock Price Target
$14.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+239.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-51,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.15 per share

Miscellaneous

Free Float
32,413,000
Market Cap
$101.03 million
Optionable
Not Optionable
Beta
1.22
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Nevan Charles Elam J.D. (Age 57)
    Founder, CEO & Acting Chairman of the Board
    Comp: $973.65k
  • Dr. Brian Kenneth Roberts M.D. (Age 48)
    Chief Medical Officer
    Comp: $738.86k
  • Mr. Daron G. Evans M.B.A. (Age 50)
    M.S., Chief Financial Officer
  • Dr. Davelyn Eaves Hood M.B.A.
    M.D., Director and Head of Scientific & Patient Affairs
  • Mr. Michael R. Deperro
    Senior VP & Head of Corporate Development
  • Mr. Michael Covarrubias
    Senior VP & Head of Program & Portfolio Management
  • Mr. Chris Milks
    VP & Head of Finance
  • Dr. Raj Agrawal M.D.
    VP & Head of Ophthalmological Clinical Development
  • Ms. Robyn Sweinhart
    VP & Head of Quality
  • Ms. Erin O'Boyle
    Senior VP & Head of Clinical Operations

RZLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Rezolute stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RZLT shares.
View RZLT analyst ratings
or view top-rated stocks.

What is Rezolute's stock price target for 2024?

3 equities research analysts have issued 1 year price targets for Rezolute's stock. Their RZLT share price targets range from $5.00 to $14.00. On average, they predict the company's share price to reach $8.67 in the next twelve months. This suggests a possible upside of 239.9% from the stock's current price.
View analysts price targets for RZLT
or view top-rated stocks among Wall Street analysts.

How have RZLT shares performed in 2024?

Rezolute's stock was trading at $0.9925 at the start of the year. Since then, RZLT shares have increased by 156.9% and is now trading at $2.55.
View the best growth stocks for 2024 here
.

Are investors shorting Rezolute?

Rezolute saw a decrease in short interest in March. As of March 15th, there was short interest totaling 214,700 shares, a decrease of 88.2% from the February 29th total of 1,820,000 shares. Based on an average daily volume of 287,300 shares, the short-interest ratio is presently 0.7 days.
View Rezolute's Short Interest
.

When is Rezolute's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RZLT earnings forecast
.

How were Rezolute's earnings last quarter?

Rezolute, Inc. (NASDAQ:RZLT) released its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.27) earnings per share for the quarter, hitting the consensus estimate of ($0.27).

What other stocks do shareholders of Rezolute own?
Who are Rezolute's major shareholders?

Rezolute's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (25.63%), Vivo Capital LLC (8.18%), Stonepine Capital Management LLC (6.99%), Nantahala Capital Management LLC (3.88%), Citadel Advisors LLC (0.87%) and UBS Group AG (0.55%). Insiders that own company stock include Brian Kenneth Roberts, Daron Evans, Genexine Inc, Gil M Labrucherie, Nevan C Elam and Young-Jin Kim.
View institutional ownership trends
.

How do I buy shares of Rezolute?

Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RZLT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners